Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg; telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: iron oxide black; iron oxide yellow; brilliant blue fcf aluminium lake; microcrystalline cellulose; croscarmellose sodium; calcium hydrogen phosphate; silicon dioxide; meglumine; povidone; mannitol; sodium hydroxide; isomalt; magnesium stearate - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

United States - English - NLM (National Library of Medicine)

cenexi hsc - methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh) - provayblue ® usp is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. this indication is approved under accelerated approval. continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials [ see clinical studies ( 14.1) ]. provayblue ® is contraindicated in the following conditions: - severe hypersensitivity reactions to methylene blue or any other thiazine dye [see warnings and precautions ( 5.2)] . - patients with glucose-6-phosphate dehydrogenase deficiency (g6pd) due to the risk of hemolytic anemia [see warnings and precautions ( 5.3,

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

the trustee for anderson family trust - boron (b) present as boric acid - powder - boron (b) present as boric acid mineral-boron-acid active 173.0 g/kg - household insecticide - boat | canteen and/or bakery and/or restaurant | caravan | commercial premises - general | domestic and/or public area | food pr - cockroach | silverfish | large cockroach | small cockroach

New Zealand - English - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - fluconazole 150mg;   - capsule - 150 mg - active: fluconazole 150mg   excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch patent blue v tekprint black sw-9008 titanium dioxide - vaginal candidiasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - fluconazole, quantity: 200 mg - capsule, hard - excipient ingredients: purified water; lactose monohydrate; maize starch; patent blue v; magnesium stearate; titanium dioxide; erythrosine; gelatin; colloidal anhydrous silica; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ozole (fluconazole) capsules, given orally, are indicated for the following conditions: - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the acute phase of cryptococcal meningitis. - maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. - treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. - secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. - serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infecctions. until such data are available, amphotericin b remains the drug of choice. - vaginal candidiasis, when topical therapy has failed. - treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therpy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 10 mg - capsule - excipient ingredients: hydrophobic colloidal silica anhydrous; pregelatinised maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate; brilliant scarlet 4r; patent blue v - - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. - post mi heart failure, - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. - for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. - for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - fluconazole 50mg; fluconazole 50mg; fluconazole 50mg - capsule - 50 mg - active: fluconazole 50mg excipient: erythrosine gelatin hydrated silica lactose monohydrate magnesium stearate patent blue v pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide active: fluconazole 50mg excipient: erythrosine gelatin hydrated silica lactose monohydrate magnesium stearate maize starch patent blue v sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide active: fluconazole 50mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate maize starch patent blue v ponceau 4r sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide - 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant 6. fluconazole 50 mg & 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: ammonia solution butyl alcohol colloidal silicon dioxide ethanol gelatin   iron oxide black isopropyl alcohol lactose monohydrate magnesium stearate maize starch patent blue v   potassium hydroxide propylene glycol purified water   shellac sodium laurilsulfate titanium dioxide   water - ozole 150 mg capsule, given orally, is indicated for vaginal candidiasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fluconazole 200mg - capsule - 200 mg - active: fluconazole 200mg excipient: ammonia solution butyl alcohol colloidal silicon dioxide erythrosine ethanol gelatin   iron oxide black isopropyl alcohol lactose monohydrate magnesium stearate maize starch patent blue v potassium hydroxide propylene glycol purified water   shellac sodium laurilsulfate titanium dioxide   water - ozole is indicated for the treatment of the following conditions: 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. ozole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseninated candidasis and other forms of invasive candidal infection, including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytoxic chemotherapy, radiotherapy or bone marrow transplant. 6. ozole 50 mg and 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.